Cannabis Law Report

OCTOBER 10, 2021

As a think tank we develop new ideas and concepts for providing medical cannabis to patients both in Germany and Europe. Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. YOUR PROFILE: Bachelor’s degree in life science, relevant scientific field required (e.g.

Clinical Trials 52

Clinical Trials Therapy Medicine Policy 52

The Cannigma

AUGUST 31, 2021

A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 161

Legislation Decriminalization Access Therapy 161

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 10 × 10. See, e.g., Jennifer M. Mitchell et al., Divito & Robert F.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JULY 25, 2022

Conversation Tackles MAPS Research Methadology & Issues Of Abuse In Therapy. Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Psychedelics Today Podcast Interviews Rick Doblin.

Medicine 52

Medicine Therapy Research and Development Business 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”. Co-author Dr Sue Sisley says that the results are promising.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 3, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

MARCH 1, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

DECEMBER 30, 2019

After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019. Erik Altieri.

Legislation 59

Legislation Patients Access Banking 59